Statement of Principles concerning rapidly progressive crescentic glomerulonephritis (Balance of Probabilities) (No. 46 of 2019)

The central concept is "rapidly progressive crescentic glomerulonephritis" as defined in subsection 7(2): a form of glomerulonephritis where there are extensive cellular crescents on histopathology and a rapid decline in renal function over weeks to months. This definition is binary and pathologically grounded: a person either meets it or does not, based on objective findings. The instrument operates on the "balance of probabilities" standard under subsection 196B(3) of the VEA, which means it requires the decision-maker to be satisfied that the connection is more probable than not, as distinct from the "reasonable hypothesis" standard used for operational service claims. The concept of "relevant service" is defined in the Schedule 1 Dictionary and is narrow: it covers eligible war service (other than operational service) under the VEA, defence service (other than hazardous service and British nuclear test defence service) under the VEA, and peacetime service under the MRCA. This means veterans with operational service or hazardous service cannot rely on this SoP and must use a different standard. The list of factors in section 9 is exhaustive: the decision-maker cannot consider other potential causes not listed, which limits discretion but also limits the scope of claims that succeed if a scientifically plausible cause is omitted. The instrument introduces timing windows that are critical: infections must be within two months before clinical onset; drugs must be within seven days before clinical onset; autoimmune disorders, infiltrative disorders, renal disorders, and malignant neoplasms must be present at the time of clinical onset. "Clinical onset" is not defined in the instrument, which creates interpretive risk. The terminal event definition in the dictionary lists five causes (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function) that allow death to be attributed to RPCGN if RPCGN contributed to that terminal event. This is expansive: a veteran who dies from pneumonia years after RPCGN diagnosis may be covered if the RPCGN contributed to the pneumonia. The incorporation mechanism in section 11 means that if a factor refers to an injury or disease covered by another SoP (for example, rheumatoid arthritis under the specified list of autoimmune disorders), the factors in that separate SoP also apply, creating a chain of presumptions.

This SoP directly binds decision-makers in the Department of Veterans' Affairs and the Military Rehabilitation and Compensation Commission when assessing claims from veterans and members who have rendered "relevant service" as defined. It affects veterans with eligible war service that is not operational service (for example, service in the Defence Force during peacetime or in non-combat roles), those with defence service that is not hazardous service or British nuclear test defence service, and members of the Australian Defence Force with peacetime service under the MRCA. The instrument does not apply to serving members on warlike service or hazardous service; they fall under different standards. The practical reach includes any person who has served and now develops RPCGN or dies from it, and whose claim for service connection is assessed under the balance of probabilities standard. Clinicians nephrologists, pathologists, and general practitioners who diagnose and manage RPCGN will be drawn into the claims process because their medical opinions determine whether the definition in subsection 7(2) is satisfied and whether any listed factor existed within the required time windows. The Repatriation Medical Authority itself is affected as the body that must maintain and update this SoP based on sound medical-scientific evidence. Legal practitioners who specialise in veterans' law must be familiar with this instrument to advise clients on whether their condition can be presumptively linked to service, and to gather evidence addressing the specific factors. The instrument indirectly affects taxpayers because every successful claim under this SoP results in ongoing compensation payments and health care costs. The exhaustive list of factors concentrates benefits on claimants with one of the specified triggers while those with causes not listed receive no assistance from this instrument, which may create inequity between claimants with medically similar but legally distinct conditions. The cross-reference mechanism in section 11 expands the scope by importing other SoPs, potentially capturing a broader class of claimants whose primary condition is a secondary consequence of a listed autoimmune disorder or infiltrative disease.

The instrument imposes no duties on claimants directly; rather, it creates a legal obligation on decision-makers to apply the prescribed factors when determining claims. Claimants have the right to have their claim assessed under this SoP if they have relevant service and satisfy at least one factor in section 9. The decision-maker must consider whether each listed factor existed and whether it is related to the person's service as required by section 10(1). If a factor exists and is service related, the decision-maker must accept the connection on balance of probabilities unless outweighed by contrary evidence. Claimants also have the right to rely on factor 9(7) (inability to obtain appropriate clinical management) but only for material contribution or aggravation of pre-existing RPCGN under section 10(2), not for original clinical onset. This is a critical limitation: a veteran who developed RPCGN during service cannot use the clinical management factor to establish initial connection. The duty of the decision-maker to apply section 11 means they must also consider any other SoP referenced if the factor involves a disease covered by another SoP. For example, if a claimant relies on factor 9(2) (autoimmune disorder) and that disorder has its own SoP, the decision-maker must apply that SoP as well. This stacking of SoPs creates a complex web of presumptions that a claimant can only satisfy by meeting each one. The decision-maker has no power to waive any factor or consider causes not listed. Claimants have no duty to prove that a factor is the sole cause; only that it exists and is service related. The instrument does not specify how the decision-maker must determine "clinical onset", leaving that to medical evidence and interpretation, which creates a right for the claimant to present expert opinion on timing. There is no explicit right to be heard or to challenge the instrument itself, but claimants can challenge its application through the Administrative Appeals Tribunal and courts. The instrument imposes no duties on third parties such as employers or medical practitioners.

This instrument contains no penalties of its own. It is not a punitive regulation; it is a guideline for benefit entitlement. Enforcement of the SoP occurs through the claims adjudication process: if the decision-maker incorrectly applies the factors or fails to consider a relevant factor, the claimant can apply for review. The VEA and MRCA provide mechanisms for internal review and external merits review by the Veterans' Review Board and the Administrative Appeals Tribunal. A decision-maker who deliberately misapplies the SoP could face disciplinary action under public service codes of conduct, but the instrument itself does not create any offence. False statements made by claimants in connection with a claim can lead to prosecution under the Criminal Code (for fraud) or under specific provisions of the VEA relating to false or misleading information, but those penalties arise from other laws, not this SoP. The practical enforcement risk is for the government: if the Department fails to apply the correct SoP, it may be compelled on review to pay benefits it would not otherwise have paid, or to pay higher arrears. Conversely, if the Department improperly denies a claim by overlooking a factor, it may face adverse cost orders or compensation. The instrument does not provide for any civil penalties against claimants or their representatives. The RMA itself is not subject to enforcement for the content of the SoP; its determinations are based on medical-scientific evidence and are reviewable only on limited grounds such as procedural error or lack of jurisdiction. The repeal of the 2010 SoP means that any claim assessed after 27 May 2019 that was pending under the old instrument must be re-assessed under this one, creating transitional enforcement questions. Because the SoP is a legislative instrument registered on the Federal Register of Legislation, failure to comply with its terms would be a legal error that could be corrected on review.

This SoP is made under subsection 196B(3) of the VEA and interacts primarily with sections 120B of the VEA and 339 of the MRCA, which mandate the use of SoPs in determining claims under the balance of probabilities standard. It does not apply to claims under subsection 196B(2) of the VEA, which governs the reasonable hypothesis standard for operational service; a separate SoP exists for that purpose. The instrument repeals the 2010 SoP (No. 82 of 2010) on commencing, so any claim that has not been finally determined before 27 May 2019 must be decided under this new SoP. Section 11 creates a dynamic interaction with other SoPs: if a factor in section 9 refers to a disease that is itself covered by another SoP (for example, systemic lupus erythematosus under the autoimmune disorder list), the factors in that other SoP apply as well, and must be read in force from time to time. This means the claimant may need to satisfy two or more SoPs in sequence. The instrument does not override the substantive provisions of the VEA or MRCA regarding standard of proof, definitions of service, or eligibility criteria; it operates within those broader frameworks. It does not interact with state or territory workers compensation laws because the veterans' scheme is a federal, exclusive compensation regime for service-related injuries and diseases. However, a veteran who has also claimed under a state scheme may have interaction issues regarding double dipping or offsets, but those are governed by VEA and MRCA provisions, not this SoP. The instrument interacts with the general law of evidence because it creates a statutory presumption that displaces the need for medical causation evidence on the specific factors. It does not interact with the Safety, Rehabilitation and Compensation Act 1988 or the Military Rehabilitation and Compensation Act 2004 beyond the specific section 339 reference. There is no interaction with criminal law except through fraud offences. The instrument is also subject to the Legislation Act 2003 for registration, tabling, and disallowance, though no disallowance is recorded in the source. The dictionary definitions are self-contained and do not automatically import definitions from other Acts unless explicitly cross-referenced as with VEA and MRCA.

The source text provides limited amendment history. The instrument itself was made on 26 April 2019, registered on the Federal Register of Legislation, and commences on 27 May 2019. It repeals the previous SoP concerning rapidly progressive crescentic glomerulonephritis No. 82 of 2010 (registered as F2010L02338), which was also made under subsection 196B(3). That prior instrument is revoked in full. No other amending instruments are listed in this text. The instrument has not been amended since its commencement, based on the text provided. It is possible that subsequent amendments have been made, but the source does not include them. The instrument is a standalone replacement, not an amendment of an existing instrument. The 2010 SoP itself may have amended earlier versions, but that history is not in the source. The instrument includes a repeal clause (section 4) that explicitly identifies the repealed instrument by its Federal Register number. This is standard drafting practice to ensure legal continuity. The instrument does not contain transitional provisions beyond section 5, which states it applies to claims to which VEA section 120B or MRCA section 339 applies, which would capture pending claims as at the commencement date. Without transitional savings, any pending claim under the 2010 SoP would be assessed under this new SoP, which could alter the outcome if factors changed. The source does not specify what changes were made from the 2010 version to this 2019 version, so a practitioner would need to compare both instruments to identify substantive differences. The dictionary definitions may have been expanded or narrowed. Without access to the 2010 SoP, no further amendment analysis is possible from this source.

The source text does not reference any litigation history. No court or tribunal decisions are cited, and no challenges to the instrument are mentioned. The instrument itself has not been judicially considered in the text. However, as a legislative instrument made under the VEA, it is subject to merits review by the Veterans' Review Board and the Administrative Appeals Tribunal, and judicial review by the Federal Court. Litigants may challenge the application of the factors, the interpretation of definitions (particularly "clinical onset", "related to service", and the temporal windows), and whether the medical-scientific evidence supports the factors listed. The phrasing of subsection 9(7) (inability to obtain appropriate clinical management) has generated litigation in the context of other SoPs, particularly around what constitutes "appropriate" clinical management and whether a subjective or objective standard applies. The definition of "relevant service" has also been litigated to determine whether particular periods of service fall under eligible war service, defence service, or peacetime service. The cross-reference mechanism in section 11 could lead to disputes when the incorporated SoP itself is amended or repealed after the claim is lodged. No specific case law is provided, so any analysis of litigation trends would be speculative. The Repatriation Medical Authority's determination of "sound medical-scientific evidence" has been challenged in other contexts, but not in this source. The instrument's balance of probabilities standard versus the reasonable hypothesis standard is a common litigation point, but that is structural to the VEA, not specific to this SoP. Without cases, the safest statement is that the litigation history is not documented in the source and would require independent research into AAT and Federal Court decisions.

Several traps await the unwary practitioner. First, "relevant service" as defined excludes operational service and hazardous service. Many veterans assume all service qualifies; it does not. A veteran with operational service cannot use this SoP and must rely on a reasonable hypothesis SoP under subsection 196B(2). Second, factor 9(7) (inability to obtain appropriate clinical management) is severely limited by section 10(2): it applies only to material contribution or aggravation of RPCGN that was suffered or contracted before or during service but did not arise out of service. It cannot be used to establish clinical onset of the disease in the first instance. Third, the timing windows are rigid: infections must be within two months before clinical onset, drugs within seven days. Missing these windows by even one day means the factor does not exist, regardless of medical plausibility. Fourth, the specified lists are exhaustive. If a person has an autoimmune disorder not listed, such as sarcoidosis (which is only in the infiltrative list) or an unlisted vasculitis, it is not a factor. Fifth, "clinical onset" is not defined in the instrument or its dictionary. This creates interpretive risk: the decision-maker may determine that clinical onset occurred before the first medical diagnosis, based on symptom history, and defeat a factor that would otherwise be satisfied. Sixth, the terminal event definition is broad but also potentially double-edged: if a person dies from a cause not on the list, death from RPCGN may not be accepted even if RPCGN was a substantial cause. Seventh, the incorporation of other SoPs via section 11 means the claimant must satisfy the factors of multiple SoPs. For example, if the claimant relies on an autoimmune disorder such as systemic lupus erythematosus, they must also satisfy the SoP for that disease, which may have its own onerous factor list. Eighth, the instrument uses the term "at the time of the clinical onset" for several factors, which requires contemporaneous evidence of the autoimmune or infiltrative disorder at that precise time, not just a general history. Ninth, the drug list includes "cocaine adulterated with levamisole" as a specific entry, which is unusual and may catch claimants who used cocaine but cannot prove adulteration. Tenth, the dictionary does not define "appropriate clinical management", leaving it to interpretation; a decision-maker may conclude that management was appropriate even if it was unavailable due to system failures. Eleventh, the instrument applies to claims under VEA section 120B and MRCA section 339, not to claims under the Safety, Rehabilitation and Compensation Act 1988 or other schemes.

For claimants and their representatives, compliance begins with obtaining a confirmed histopathological diagnosis of rapidly progressive crescentic glomerulonephritis that meets the definition in subsection 7(2): extensive cellular crescents on histopathology and a rapid decline in renal function over weeks to months. The medical evidence must be documented. Next, identify which of the seven factors in section 9 may apply. Gather evidence of timing for each potential factor. For infections, document the date of infection and its occurrence within two months before clinical onset. For autoimmune disorders, infiltrative disorders, and renal disorders, obtain evidence confirming the diagnosis and showing it existed at the time of clinical onset. For malignant neoplasms, demonstrate the neoplasm was present at clinical onset. For drugs, document the specific drug from the specified list and show it was taken within seven days before clinical onset. For factor 9(7), document the inability to obtain appropriate clinical management for RPCGN, but only if the disease was pre-existing and being aggravated during service. Ensure the factor is related to relevant service as required by section 10(1). For factor 9(7), confirm the disease was suffered or contracted before or during service but did not arise out of service, then show the inability to obtain management materially contributed to aggravation. If the factor involves a disease covered by another SoP, comply with that SoP as well under section 11. Maintain a complete chronology of service, clinical events, and factor existence. For decision-makers, confirm the claim falls under VEA section 120B or MRCA section 339 and that the person has relevant service as defined. Assess whether at least one factor exists based on the evidence, and whether it is related to service. If a factor is met, accept the connection unless contrary evidence outweighs it. Document the reasoning for each factor considered. For death claims, apply the terminal event definition and determine whether RPCGN contributed to the terminal event. Do not consider factors not listed. Be alert to the timing windows and the exhaustive nature of the lists. Record the version of the SoP applied and any transitional issues if the claim straddled the repeal date. Practitioners should regularly check the Federal Register of Legislation for any subsequent amendments to this SoP or to any incorporated SoPs, as section 11 applies them as in force from time to time. The absence of a definition for "clinical onset" requires careful medical evidence; consider commissioning a specialist opinion that identifies the earliest plausible date of clinical onset based on clinical records.